Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
Regeneron Pharmaceuticals Inc(REGN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for REGN
09/15/2026: REGN (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Regeneron Pharmaceuticals is a leading biotechnology company recognized for its proprietary genetic technology and successful development of blockbuster medicines. Its primary strengths include a highly efficient R&D engine and a dominant market position in ophthalmology and immunology with flagship products like EYLEA and Dupixent. The core investment story centers on the continued expansion of these products and the advancement of a high-potential oncology pipeline. However, investors must monitor risks related to patent expirations, intensifying competition, and regulatory drug pricing pressures. Regeneron is well-suited for growth-oriented investors, though it carries the volatility and risks typical of the biotechnology sector.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company has a consistent track record of developing innovative, high-growth blockbuster therapies. |
| Momentum investor | Mixed fit | Momentum depends on positive clinical data readouts and regulatory approvals which can create volatility. |
| Value investor | Weak fit | The stock often trades at a premium valuation reflecting its high growth and strong patent-protected IP. |
| Dividend investor | Weak fit | The company does not pay a dividend and prioritizes capital reinvestment into R&D. |
| Low-risk investor | Weak fit | The inherent risks of drug development and biotech regulatory cycles create significant price volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | Clinical trial results and regulatory decisions can lead to significant short-term stock swings. |
| Valuation risk | Medium | As a growth-oriented stock, valuation is sensitive to changes in growth expectations or interest rates. |
| Competition risk (Biologics/Therapeutics) | High | Incumbent and new-entrant competition for key products like EYLEA and Dupixent poses a constant threat to market share. |
| Business quality | Strong | The company possesses high-quality, durable intellectual property and a proven discovery engine. |
| Dividend income | Low / none | Investors should not rely on this stock for current income. |
| Execution risk | Medium | Successful commercialization of late-stage pipeline candidates is essential for long-term growth. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 49.89% | Avg. Invested days 65 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/15/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 81.72B USD | Price to earnings Ratio 19.65 | 1Y Target Price 849.32 |
Price to earnings Ratio 19.65 | 1Y Target Price 849.32 | ||
Volume (30-day avg) 665.4K shares | Beta 0.19 | 52 Weeks Range 538.24 - 859.34 | Updated Date 09/15/2026 |
52 Weeks Range 538.24 - 859.34 | Updated Date 09/15/2026 | ||
Dividends yield (FY) 0.47% | Basic EPS (TTM) 40.4 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Sales | Revenue generated from the direct sale of medicines like EYLEA and Libtayo. | Most revenue comes from the direct sale of proprietary medicines to healthcare providers. |
| Collaboration Revenue | Profit-sharing and milestone payments from partners like Sanofi for drugs like Dupixent. | The company generates significant income by sharing the success of drugs with other pharmaceutical companies. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 19.65 | Forward PE 14.14 | Enterprise Value 75.17B | Price to Sales(TTM) 5.26 |
Enterprise Value 75.17B | Price to Sales(TTM) 5.26 | ||
Enterprise Value to Revenue 4.84 | Enterprise Value to EBITDA 13.07 | Shares Outstanding 101.14M | Shares Floating 95.79M |
Shares Outstanding 101.14M | Shares Floating 95.79M | ||
Percent Insiders 2.08 | Percent Institutions 93.6 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Regeneron Pharmaceuticals Inc
Exchange NASDAQ | Headquarters Tarrytown, NY, United States | ||
IPO Launch date 1991-04-02 | Co-Founder, President, CEO & Co-Chairman Dr. Leonard S. Schleifer M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15410 | Website https://www.regeneron.com |
Full time employees 15410 | Website https://www.regeneron.com | ||
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.